Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic antibodies in murine models of human autoimmune diseases. After obtaining his Ph.D., he combined two postdoctoral grants in Barcelona (Metastasis and Transformation group in Bellvitge Biomedical Research Center) and in Valencia (Autoimmune Pathology Lab in…

Read More

Dr. William Williams of Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. William Williams of  Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into the clinic and established proof of concept in several disease areas. At GlaxoSmithKline he worked to bring several molecules into the clinic, ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug…

Read More

Speaker Interview with Sebastien Tabruyn for the 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Interview with Sebastien Tabruyn for the 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). After 10 years of experience as Project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 as Head of Molecular Biology and Oncology. Sebastien Tabruyn published 30 peer-reviewed publications in the field of Oncology, Angiogenesis, Inflammation and Immunity In a recent interview with MarketsandMarkets, Mr. Sebastien Tabruyn shared his thoughts on the current challenges that…

Read More

What do MNM Analysts have to say about the Immuno Oncology Market?

What do MNM Analysts have to say about the Immuno Oncology Market?

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC’s, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case…

Read More

Speaker Interview with Dr. Susan Astley for MarketsandMarkets Biomarker and Companion Diagnostics Conference

Speaker Interview with Dr. Susan Astley for MarketsandMarkets Biomarker and Companion Diagnostics Conference

London, September 3, 2019 – MarketsandMarkets recently interviewed Dr. Susan Astley, Division of Informatics, Imaging & Data Sciences, University of Manchester regarding MarketsandMarkets Biomarker and Companion Diagnostics Conference taking place on 3rd – 4th October 2019 at Radisson Blu Edwardian, Grafton, London, UK Q. What are the recent advances in Biomarker research/commercialization and current challenges that need immediate attention? A. The era of personalised medicine is with us. Biomarkers are crucial to identify those at risk of particular diseases, and those who would benefit from different preventative or therapeutic interventions….

Read More

Emerging 4 Trends – Cancer Immunotherapy Biomarkers

Emerging 4 Trends – Cancer Immunotherapy Biomarkers

Cancer immunotherapy has turned out to be a revolutionary treatment to fight against this largest group of diseases in the world. The artificial stimulation of the immune system enhances the natural ability of the body to fight against cancer. The field on immunotherapy shows a great potential in treating a wide range of types of cancers. Over 8,000 cancer immunotherapy experiments are taking place in clinical trials along with which includes rapid development of biomarkers. The smart and effective immunotherapy is already transforming cancer treatment approach while biomarkers, in addition,…

Read More